Beam Therapeutics reports initial Phase 1/2 data for BEAM — 301 in glycogen storage disease type Ia trial
Beam Therapeutics flagged initial Phase 1/2 results for BEAM-301 in glycogen storage disease type Ia for presentation at ESGCT. Data showed signs of restored patients’ ability to maintain glucose levels following a single dose, with stronger effects at higher dosing. Patients reduced reliance on frequent starch dosing,